Ameriprise Financial Inc. boosted its stake in shares of Cambrex Co. (NYSE:CBM) by 6.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 313,817 shares of the biotechnology company’s stock after buying an additional 17,636 shares during the period. Ameriprise Financial Inc. owned approximately 0.96% of Cambrex worth $17,260,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the stock. Stifel Financial Corp increased its position in Cambrex by 0.8% during the 2nd quarter. Stifel Financial Corp now owns 4,580 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 37 shares in the last quarter. YorkBridge Wealth Partners LLC increased its position in Cambrex by 5.2% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 97 shares in the last quarter. Mark Sheptoff Financial Planning LLC increased its position in Cambrex by 2.5% during the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 4,000 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 99 shares in the last quarter. Arizona State Retirement System increased its position in Cambrex by 0.6% during the 2nd quarter. Arizona State Retirement System now owns 16,976 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 100 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Cambrex by 0.5% during the 2nd quarter. PNC Financial Services Group Inc. now owns 22,178 shares of the biotechnology company’s stock valued at $1,325,000 after buying an additional 119 shares in the last quarter.

CBM has been the subject of a number of analyst reports. Craig Hallum reaffirmed a “buy” rating and set a $60.00 price objective (down previously from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. BidaskClub lowered Cambrex from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. Finally, ValuEngine downgraded Cambrex from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $62.33.

In other Cambrex news, CEO Steven M. Klosk sold 4,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the sale, the chief executive officer now directly owns 87,328 shares in the company, valued at approximately $4,799,546.88. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 2.48% of the company’s stock.

Shares of Cambrex Co. (CBM) opened at $49.90 on Thursday. Cambrex Co. has a 52 week low of $42.55 and a 52 week high of $62.95. The company has a market capitalization of $1,629.05, a price-to-earnings ratio of 15.68, a price-to-earnings-growth ratio of 1.12 and a beta of 2.26.

Cambrex (NYSE:CBM) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.47 by $0.08. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. The business had revenue of $112.60 million for the quarter, compared to the consensus estimate of $108.44 million. During the same period last year, the business posted $0.47 EPS. The company’s revenue was up 13.4% compared to the same quarter last year. analysts expect that Cambrex Co. will post 2.97 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/12/14/ameriprise-financial-inc-has-17-26-million-position-in-cambrex-co-cbm.html.

Cambrex Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.